COVID-19 and Muscular Dystrophies, and R&D for Rare Disorders: Sharon Hesterlee, PhD
March 16th 2021The executive vice president and chief research officer of the MDA offered her perspective on the ongoing conversations about and impact of the pandemic on the care of patients with muscular dystrophies.
Donanemab Slows Decline on iADRS in Early Alzheimer Disease, Mixed Secondary Outcomes
March 15th 2021Despite showing better composite scores for cognition and ability to perform activities of daily living, a number of the secondary outcomes showed mixed results with the Eli Lilly investigational agent.
Pediatric-Onset MS Associated With Worse Long-Term Socioeconomic Outcomes
March 15th 2021Persons with pediatric-onset MS received higher rates of disability benefits, sickness absence days in their youngest age period, and disability pension days in their oldest age period than those without MS.